[Immunologic thrombocytopenic purpura: a revolution of biological therapy?].
Bierling
Philippe
P
Laboratoire immunologie-leucoplaquettaire, EFS Ile-de-France. philippe.bierling@efs.sante.fr
Godeau
Bertrand
B
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D053628:Receptors, Thrombopoietin / Q000819:agonists; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007155:Immunologic Factors; D053628:Receptors, Thrombopoietin; D000069283:Rituximab